New Correctional Indication for Monoclonal Antibody (Regen-COV) for COVID-19

Share/Print
Posted Aug 25, 2021

On July 30, 2021, the FDA modified its Emergency Use Authorization (EUA) for Regen-COV, a medication used in the treatment of COVID-19 infection. Regen-COV is a monoclonal antibody (MCAb) used in the management of the SARS-CoV-2 pandemic. Regen-COV is now approved under the EUA for use in correctional populations to prevent COVID infection under specific conditions. 

NCCHC, American Jail Association, National Sheriffs' Association, and American College of Correctional Physicians have created an information sheet to make sure health care teams are aware of a specific indication for the use of MCAb in correctional settings. This is not a guidance, or endorsement nor meant to establish a standard of care; it is provided for your information to address as clinicians see fit.

Read the full statement >>

Additional links:

FDA FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF REGEN-COVTM (casirivimab and imdevimab)

FACT SHEET FOR PATIENTS, PARENTS AND CAREGIVER